Erasca, Inc. pursues a modality-agnostic strategy targeting the RAS/MAPK pathway in cancers through its clinical-stage pipeline. The company’s two lead candidates, ERAS-0015 and ERAS-4001, are in Phase 1 studies supported by exclusive licensing agreements, notably with Joyo expanding territorial rights in early 2026. Despite consistent operating losses driven by R&D investments, Erasca’s financial position remains strong with significant cash reserves. Future growth hinges on clinical data readouts, execution of combination therapy strategies, and navigating a competitive landscape alongside regulatory hurdles typical of oncology drug development.